Predictors of Long-Term Survival in Patients with Lung Cancer Included in the Randomized Spanish Lung Cancer Group 0008 Phase II Trial Using Concomitant Chemoradiation with Docetaxel and Carboplatin plus Induction or Consolidation Chemotherapy

Docetaxel and Carboplatin Plus Induction or Consolidation Chemotherapy

Pilar Garrido; Rafael Rosell; Bartomeu Massutí; Felipe Cardenal; Vicente Alberola; Manuel Dómine; Inmaculada Maeztu; Alfredo Ramos; Antonio Arellano


Clin Lung Cancer. 2009;10(3):180-186. 

In This Article


To date, there are no clinical or molecular predictors of OS for selecting treatment in patients with NSCLC. Despite the small sample size and retrospective nature of the current study, it highlights the importance of completing treatment, although no pretreatment variables surfaced as prognostic factors. In the future, an increased understanding of tumor biology and other interindi-vidual differences could lead to improved outcomes.